A drug that blocks neurotransmitters could reduce nausea and vomiting caused by chemotherapy, research co-authored by a Sanford Health physician and published in the New England Journal of Medicine finds. Sanford oncologist and cancer researcher Steven Powell, M.D., was among a team of researchers who discovered that the drug olanzapine, which is FDA approved for use as an antipsychotic agent, significantly improved nausea prevention in patients who were receiving chemotherapy for cancer treatment. The drug blocks neurotransmitters involved with nausea and vomiting.
‘We’ve long known the nausea and vomiting that come along with chemotherapy are a major problem and affect the quality of life of our patients,’ said Powell. ‘The findings of this study, fortunately, provide physicians with a tool to better address the needs of those they are treating for cancer.’ Researchers noted that within the first day after treatment, 74 percent of study participants experienced no nausea or vomiting when their chemotherapy was paired with olanzapine. When a placebo was used instead of olanzapine, that figure dropped to 45 percent. This benefit continued for five days after chemotherapy treatment for many patients.
Sanford Health www.sanfordresearch.org/newsevents/news/NewsDetail25278.cfm?Id=0,1887
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:38:032020-08-26 14:38:21New treatment to prevent nausea, vomiting caused by chemotherapy
The 32nd Korea International Medical & Hospital Equipment Show held in Seoul from 17 to 20 March showcased Korea’s important medical equipment industry.
Over the years, KIMES has grown into one of the major trade shows in Asia. This year, the event gathered more than 73,000 visitors over 38,808 square meters of exhibition space. One of its main advantages is that it acts as a showcase for Korea’s particularly strong medical equipment industry. Indeed, out of the 1,152 companies from 37 countries who were exhibiting this year, 548 were Korean manufacturers and the show provided an ideal setting for highlighting the increasingly important role played by leading Korean companies such as Samsung, Listem, JW Medical, DK Medical, BIT Computer and Alpinion to name but a few. As a platform enabling Korea’s medical device industry to show its latest equipment and technology alongside leading global players like GE, Fuji, Shimadzu and Hitachi, KIMES has succeeded in attracting numerous contingents of foreign visitors especially from the Asia region who have a strong purchasing power, including officials in medical institutions and hospitals, radiologists, medical laboratory specialists, pharmacists and emergency medical personnel. The number of foreign visitors has increased significantly this year, reaching 3563 medical professionals from 86 countries, a growth of 17.2% versus 2015. Over the last 5 years, the total of foreign visitors has grown by 184% compared with 19% for domestic visitors. Unsurprisingly, China is top of the list accounting for more than 30% of the total of foreign visitors, followed by South East Asia with nearly 20% and Japan. A post show survey of exhibitors conducted by the organizers showed a majority of them satisfied with the results of their participation and over 70% committing to exhibit again in 2017.
www.kimes.kr
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:38:032020-08-26 14:38:25KIMES 2016: foreign visitor surge reflects growing interest in Korean medical market
An outcomes study led by Alexi Wright, MD, MPH, a researcher and a gynecological oncologist in the Susan F. Smith Center for Women’s Cancers at Dana-Farber, surveyed families of older patients who had died of advanced lung and colorectal cancer, asking what factors were associated with ‘excellent’ end-of-life care for their loved ones. The families were more likely to assess care as excellent – by relatively large margins – when:
the patient had hospice care for more than three days, compared with fewer than three days or none;
the individual wasn’t admitted to an intensive care unit (ICU) in the last 30 days of life;
the patient died at home or some other location outside the hospital, such as a hospice facility.
‘Our study findings are a powerful argument for the importance of advance care planning,’ Wright said. ‘The more information patients have, the more likely they are to receive the kind of medical care they want near death. And patients’ deaths influence family members’ perceptions of their quality of care.’ Wright reported that end-of-life care could be of higher quality if there are efforts to enroll patients in hospice earlier – not when death is imminent – and to avoid intensive care unit admissions in the final weeks. Terminally ill patients should have the legal option to choose physician-assisted death, even if – as is often the case in USA States where it is legal- they don’t use it, wrote Susan Block, MD, founding chair, Department of Psychosocial Oncology and Palliative Care at Dana-Farber and two other authors of a ‘Viewpoint’ opinion piece. Patients nearing the end of life want control over their bodies and their lives as ‘a small measure of self-preservation,’ they noted. Such individuals can gain peace of mind when they have a ‘back-up’ plan, they added. ‘When physicians are willing to explore and work with a patient requesting physician-assisted death, patients can experience substantial benefits that are more apparently under an open legal process,’ said the authors.
Dana-Farber Cancer Institute http://tinyurl.com/jx6wwxz
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:38:032020-08-26 14:38:06Researchers advocate improvements in end-of-life care
The microbiome of patients admitted to the intensive care unit (ICU) at a hospital differs dramatically from that of healthy patients, according to a new study. Researchers analysing microbial taxa in ICU patients’ guts, mouth and skin reported finding dysbiosis, or a bacterial imbalance, that worsened during a patient’s stay in the hospital. Compared to healthy people, ICU patients had depleted populations of commensal, health-promoting microbes and higher counts of bacterial taxa with pathogenic strains – leaving patients vulnerable to hospital-acquired infections that may lead to sepsis, organ failure and potentially death. What makes a gut microbiome healthy or not remains poorly defined in the field. Nonetheless, researchers suspect that critical illness requiring a stay in the ICU is associated with the loss of bacteria that help keep a person healthy. The new study, which prospectively monitored and tracked changes in bacterial makeup, delivers evidence for that hypothesis. ‘The results were what we feared them to be,’ says study leader Paul Wischmeyer, an anesthesiologist at the University of Colorado School of Medicine. ‘We saw a massive depletion of normal, health-promoting species.’ Wischmeyer notes that treatments used in the ICU – including courses of powerful antibiotics, medicines to sustain blood pressure, and lack of nutrition – can reduce the population of known healthy bacteria. An understanding of how those changes affect patient outcomes could guide the development of targeted interventions to restore bacterial balance, which in turn could reduce the risk of infection by dangerous pathogens. Previous studies have tracked microbiome changes in individual or small numbers of critically ill patients, but Wischmeyer and his collaborators analysed skin, stool, and oral samples from 115 ICU patients across four hospitals in the United States and Canada. They analysed bacterial populations in the samples twice – once 48 hours after admission, and again after 10 days in the ICU (or when the patient was discharged). They also recorded what the patients ate, what treatments patients received, and what infections patients incurred. The researchers compared their data to data collected from a healthy subset of people who participated in the American Gut project dataset. (American Gut is a crowd-sourced project aimed at characterizing the human microbiome by the Rob Knight Lab at the University of California San Diego.) They reported that samples from ICU patients showed lower levels of Firmicutes and Bacteroidetes bacteria, two of the largest groups of microbes in the gut, and higher abundances of Proteobacteria, which include many pathogens. Wischmeyer was surprised by how quickly the microbiome changed in the patients. ‘We saw the rapid rise of organisms clearly associated with disease,’ he says. ‘In some cases, those organisms became 95 percent of the entire gut flora – all made up of one pathogenic taxa – within days of admission to the ICU. That was really striking.’ Notably, the researchers reported that some of the patient microbiomes, even at the time of admission, resembled the microbiomes of corpses. ‘That happened in more people than we would like to have seen,’ he says. American Society of Microbiology http://tinyurl.com/hz98ug9
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:38:032020-08-26 14:38:10ICU patients lose helpful gut bacteria within days of admission
A team of researchers have discovered a new way for early detection of a potentially deadly fungal infection in patients with suppressed immune systems such as those being treated for leukemia or who have had an organ transplant. A multidisciplinary research group led by Allan Brasier of The University of Texas Medical Branch at Galveston. Patients receiving leukemia chemotherapy treatments, bone marrow stem cell transplants or lung transplants are some of those at risk for serious infection by the disease-causing Aspergillus fungus, a common mould in the environment that easily becomes airborne. When inhaled, the mould colonizes the respiratory tract. In patients with immune suppression from their chemotherapy treatment, the mould invades into the bloodstream where it spreads and infects several organs including the liver, lungs and brain. People with normal immune systems are able to destroy the inhaled mould without becoming infected. Despite close monitoring for infection and aggressive anti-fungal therapy in vulnerable people, the fatality rates are as high as 50 to 90 percent depending on a patient’s underlying disease and site of infection. While early diagnosis can improve the patient’s outcome, timely detection of the infection is difficult. Currently, the infection is diagnosed with X-rays and tests that measure levels of fungal molecules that produce an immune reaction in a patient’s blood. These tests are not very accurate and often can lead to a wrong diagnosis. The study describes how the team studied patients undergoing chemotherapy for leukemia, bone marrow transplants and lung transplants from several of the collaborating institutions and identified, confirmed and evaluated a new method of detecting the infectious mould in patients with leukemia. Similar people with no health conditions participated in the study as a comparison group. The test results for the mould were different for each group of patients, so future commercial diagnostic tests using this technology should be tailored for different medical conditions commonly linked with this infection. Brasier, director of UTMB’s Institute for Translational Sciences, said the breakthrough was ‘an example of successful collaboration that brought together experts in several different scientific fields to approach a difficult problem.’ The team’s discovery could translate to refined diagnostics, earlier treatment and improved survival for patients affected by this infection. More studies will be needed to confirm and validate this panel as a diagnostic test in independent patients.
The University of Texas Medical Branch at Galveston http://tinyurl.com/hezj57l
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:38:032020-08-26 14:38:14New method of diagnosing deadly fungal lung infection in leukemia patients discovered
A simple phone checklist can help detect tell-tale changes in the health status of people receiving nonmedical home care, according to the findings of a pilot study led by investigators at Harvard Medical School.
Results of the research are based on a program that requires home-care aides to record changes in status during a telephone clockout at the end of each shift.
The research was conducted in collaboration with Right at Home, a senior home care provider, and ClearCare, a company that provides a software platform for homecare agencies.
Analysis of the data captured over a six-month period across 22 Right at Home agencies reveals that changes in clinical status are relatively common — occurring in 2 percent of all caregiver shifts and affecting, on average, 2 percent of recipients. The majority of changes were in behaviour (17 percent) and skin condition (16 percent), followed by changes in eating or drinking behaviour (14 percent) and ability to stand or walk (9 percent).
The results, researchers said, underscore the potential of real-time monitoring systems to spot problems and avert complications before they escalate enough to require hospitalization. Indeed, over the course of the six-month trial, 14 percent of the home-care recipients were hospitalized.
Recipients of non-medical home care often have chronic health conditions that lead to hospitalizations, some of which may be preventable.
The research team cautioned that whether the real-time monitoring system could, in fact, prevent hospitalizations and reduce cost of care remains unknown. That, they said, is the subject of an ongoing randomized trial across 400 home-care locations in the United States. However, the research team said, the fact that a basic phone questionnaire could capture important indicators in clinical status points to the value of harnessing simple technologies to monitor those receiving care at home.
‘Millions of elderly Americans receive supportive home-care services each year, and many of them require frequent hospitalizations, so we set out to determine whether a simple real-time checklist could help improve outcomes and lower health care spending,’ said study leaderDavid Grabowski, Ph.D., professor of health care policy at Harvard Medical School. ‘Our results are a first step to answering that question.’
Under the pilot program, home caregivers were required to do a phone clock out at the end of their shifts. Caregivers receive an automated phone message prompting them to report any changes in health status. The message included a list of questions pertaining to changes in mental, neurologic, gastrointestinal, urinary and other indicators. Any changes reported via the automated system were immediately dispatched to a manager at the home-care agency office for further assessment and triage. The care manager determined whether the condition required closer monitoring, a change in care, a call into the doctor’s office or all of the above. The idea, researchers said, is to prevent complications before they become grave enough to require hospitalization.
Patients who may benefit the most include those with chronic conditions such as diabetes, neurologic disorders or cardiovascular disease, in whom even seemingly innocuous changes could spell bigger trouble. That theme, researchers said, emerged clearly in a series of interviews with home-care workers. For example, one manager relayed the story of a person with diabetes whose caregiver reported a foot ulcer through the phone-based checklist. Normally, that injury would not have been reported until the end of the week, but because of the prompt alert, the care manager reached out to the patient’s nurse, who initiated treatment immediately. One week later, the wound had healed. Sores, wounds and injuries are particularly dangerous in people with diabetes and can lead to rapid decay of tissue and, in some cases, limb amputations.
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:38:032020-08-26 14:38:18Phone checklist can help detect changes in clinical status among home care recipients
Researchers at UBC and the Paul Scherrer Institut (PSI) in Switzerland have created a microneedle drug monitoring system that could one day replace costly, invasive blood draws and improve patient comfort.
The new system consists of a small, thin patch that is pressed against a patient’s arm during medical treatment and measures drugs in their bloodstream painlessly without drawing any blood. The tiny needle-like projection, less than half a milimetre long, resembles a hollow cone and doesn’t pierce the skin like a standard hypodermic needle.
‘Many groups are researching microneedle technology for painless vaccines and drug delivery,’ said researcher Sahan Ranamukhaarachchi, a PhD student and Vanier scholar in UBC’s faculties of applied science and pharmaceutical sciences, who developed this technology during a research exchange at PSI. ‘Using them to painlessly monitor drugs is a newer idea.’
Microneedles are designed to puncture the outer layer of skin, which acts as a protective shield, but not the next layers of epidermis and the dermis, which house nerves, blood vessels and active immune cells.
The microneedle created by Ranamukhaarachchi and his colleagues was developed to monitor the antibiotic vancomycin, which is used to treat serious infections and is administered through an intravenous line. Patients taking the antibiotic undergo three to four blood draws per day and need to be closely monitored because vancomycin can cause life-threatening toxic side effects.
The researchers discovered that they could use the fluid found just below the outer layer of skin, instead of blood, to monitor levels of vancomycin in the bloodstream. The microneedle collects just a tiny bit of this fluid, less than a millionth of a millilitre, and a reaction occurs on the inside of the microneedle that researchers can detect using an optical sensor. This technique allows researchers to quickly and easily determine the concentration of vancomycin.
‘This is probably one of the smallest probe volumes ever recorded for a medically relevant analysis,’ said Urs Hafeli, associate professor in UBC’s faculty of pharmaceutical sciences.
‘The combination of knowhow from UBC and PSI, bringing together microneedles, microfluidics, optics and biotechnology, allowed us to create such a device capable of both collecting the fluid and performing the analysis in one device,’ said Victor Cadarso, a research scientist and Ambizione Fellow at PSI.
University of British Columbia news.ubc.ca/2016/07/25/scientists-develop-painless-and-inexpensive-microneedle-system-to-monitor-drugs/
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:38:032020-08-26 14:38:21Painless and inexpensive microneedle system to monitor drugs
A novel measure for assessing the body’s response to surgery may allow for better anesthesia management in the O.R., less pain when regaining consciousness from anesthesia and better postoperative outcomes, according to a study. The measure, called the nociception (pain) level index, allowed physicians to more accurately evaluate responses to painful stimulation in patients under general anesthesia, compared to traditional measures. ‘There’s currently no standardized, objective method for physicians to monitor the effectiveness of pain-relieving drugs being administered during surgery,’ said Ruth Edry, M.D., lead study author and senior physician anesthesiologist at Rambam Medical Centre in Haifa, Israel. ‘Not effectively monitoring bodily responses to painful stimulation can lead to insufficient amounts of pain medication being administered, which can result in the patient having severe pain upon regaining consciousness from anesthesia, while too much medication may cause other side effects such as nausea and vomiting or respiratory complications.’ Under general anesthesia, patients are unconscious, but their body still shows reflex responses to the surgical procedure, including changes in heart rate, blood pressure, eyes tearing or sweating. These unwanted reflexes can in some cases be dangerous, and anesthesiologists adjust the amount of anesthesia and pain medication when they occur. The nociception (pain) level index, which uses an algorithmic combination to process multiple hormonal and neurological reactions, aims to provide a better, earlier measure of the body’s reflex response to painful stimulation during surgery, compared to the traditional monitoring of individual factors such as changes in heart rate or blood pressure. In the study, 58 patients who had general anesthesia for a variety of different surgical procedures were examined. Routine anesthesia monitoring was supplemented with a pain monitoring device (PMD-100; Medasense Biometrics; Ramat-Gan, Israel), which generated the nociception (pain) index. The patients’ index was compared to individual, more traditional measures, including heart rate and blood pressure. This index was assessed at several stages including intubation and skin incision, which were designated ‘noxious’ stimuli that would be painful in the conscious person, and where then compared to other non-painful periods. Compared to other accepted monitors for measuring the body’s response to painful stimulation during surgery, the nociception (pain) index better discriminated presumed pain-causing stimuli from non-pain-causing stimuli. The index also accurately quantified the body’s response to increasingly more painful stimulation, with high sensitivity and specificity, as well as showed a decrease when pain medication was administered. ‘Our results demonstrate the superiority of combining multiple physiologic measures over any individual parameter in the evaluation of the body’s response to pain during surgery,’ said Dr. Edry. ‘The article presents an effective index for trending the body’s response to painful stimulation in the anesthetized patient. Once in clinical practice, we can conduct large-scale studies to better assess the influence of this monitor on patient outcomes.’
The American Society of Anesthesiologisthttp://tinyurl.com/johadqm
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:38:032020-08-26 14:38:25Novel non-invasive monitor accurately assesses patients’ response to painful stimulation during surgery
Among patients experiencing some symptoms of depression, the use of a web-based guided self-help intervention reduced the incidence of major depressive disorder over 12 months compared with enhanced usual care, according to a study. Major depressive disorder (MDD) is a common condition associated with substantial illness and economic costs. It is projected that MDD will be the leading cause of premature mortality and disability in high-income countries by 2030. Evidence-based treatments for MDD are not very successful in improving functional and health outcomes. Attention has increasingly been focused on the prevention of MDD. Claudia Buntrock, M.Sc., of Leuphana University Lueneburg, Germany, and colleagues randomly assigned 406 adults with sub-threshold depression (some symptoms of depression, but no current MDD per certain criteria) to either a web-based guided self-help intervention (cognitive-behavioural and problem-solving therapy supported by an online trainer; n = 202) or a web-based psycho-education programme (n = 204). All participants had unrestricted access to usual care (visits to the primary care clinician). Among the patients (average age, 45 years; 74 percent women), 335 (82 percent) completed the telephone follow-up at 12 months. The researchers found that 55 participants (27 percent) in the intervention group experienced MDD compared with 84 participants (41 percent) in the control group. The number needed to treat to avoid 1 new case of MDD was 6. ‘Results of the study suggest that the intervention could effectively reduce the risk of MDD onset or at least delay onset,’ the authors write. ‘Further research is needed to understand whether the effects are generalizable to both first onset of depression and depression recurrence as well as efficacy without the use of an online trainer.’
The Health Industry Summit (tHIS) 2016 was held in Shanghai at the National Exhibition and Convention Centre from 17 to 20 April.
The organizer posted a record 380,000 entry scans, 216,784 professional visitors and more than 55,000 exhibiting staff to the venue over four days. In preparation of the large concentration of visitors, the city of Shanghai initiated its municipal level security mechanism and increased the frequency of the subway to divert the large crowds and dense traffic to the venue. Hotels were also fully booked in Shanghai during the event period. Only in its second edition, tHIS has already been firmly established as the world’s largest health industry event with over 330,000 square meters of exhibition space and 107 individual conferences. Key events included China’s three top medical equipment and pharmaceutical exhibitions (CMEF, PHARMCHINA and API China) and the leading healthcare investment forum – Healthcare China 2016. This year’s investment forum was co-organized by Reed Sinopharm, JP Morgan Asset management, CICC and Sinopharm Capital and was attended by more than 700 selected investors and institutions. The exhibition featured the entire industry value chain and presented some of the latest cutting edge technology including genetic diagnostics, rehabilitation robotics, wearable tech, 3D printing and more. 6,900 exhibiting companies from 30 countries were at the show presenting tens of thousands of products and services. Well-known healthcare equipment giants like GE, United Imaging, Siemens, Philips and Mindray as well as major pharmaceutical groups in China like Sinopharm, Shanghai Pharma and CR Pharmaceuticals were in attendance with major stand presence. Natural Health and Nutrition Expo were among the fastest growing segments in the portfolio, helped by the expected population boom in light of the reversal of the single child policy as well as a growing health-conscious middle class in China. With the start of China’s 13th Five-year plan in 2016, the ‘Health China 2020’ programme focusing on the co-development of healthcare, pharmaceutical production and health insurance has put the health industry among the top priorities for development in China and part of the national strategy. Companies in China not traditionally associated with healthcare have also shifted major investment and resources into the sector, many renaming their company in the process to reflect this focus in industry coverage. International giants with the likes of Alibaba, Lenovo, Fosun and Wanda Group have all taken a foothold into key segments of the industry in anticipation of major opportunities in the future. The Health Industry Summit is organized by Reed Sinopharm, a joint venture between the world’s leading event organizer Reed Exhibitions and China’s leading state-owned pharmaceutical group Sinopharm. Its next edition will be held in May 2017 in Shanghai.
www.thishealthsummit.com/en/index.jhtml
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:38:032020-08-26 14:38:10Reed Sinopharm hosts world’s largest healthcare event – tHIS in Shanghai
We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.
Google Analytics Cookies
These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
Other external services
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.
Privacy Beleid
U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.